JP2010513555A - 眼内使用のための環状脂質インプラントの製造法 - Google Patents
眼内使用のための環状脂質インプラントの製造法 Download PDFInfo
- Publication number
- JP2010513555A JP2010513555A JP2009543071A JP2009543071A JP2010513555A JP 2010513555 A JP2010513555 A JP 2010513555A JP 2009543071 A JP2009543071 A JP 2009543071A JP 2009543071 A JP2009543071 A JP 2009543071A JP 2010513555 A JP2010513555 A JP 2010513555A
- Authority
- JP
- Japan
- Prior art keywords
- implant
- biodegradable polymer
- polymer
- therapeutic agent
- cyclic lipid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000007943 implant Substances 0.000 title claims abstract description 336
- -1 cyclic lipid Chemical class 0.000 title claims abstract description 159
- 238000004519 manufacturing process Methods 0.000 title claims description 25
- 239000003814 drug Substances 0.000 claims abstract description 179
- 229940124597 therapeutic agent Drugs 0.000 claims abstract description 120
- 238000000034 method Methods 0.000 claims abstract description 77
- 230000008569 process Effects 0.000 claims abstract description 10
- AQOKCDNYWBIDND-FTOWTWDKSA-N bimatoprost Chemical group CCNC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)CCC1=CC=CC=C1 AQOKCDNYWBIDND-FTOWTWDKSA-N 0.000 claims description 153
- 229920000642 polymer Polymers 0.000 claims description 143
- 229960002470 bimatoprost Drugs 0.000 claims description 135
- 229920002988 biodegradable polymer Polymers 0.000 claims description 104
- 239000004621 biodegradable polymer Substances 0.000 claims description 104
- 230000001225 therapeutic effect Effects 0.000 claims description 89
- 239000000203 mixture Substances 0.000 claims description 88
- 229920000954 Polyglycolide Polymers 0.000 claims description 36
- 239000004633 polyglycolic acid Substances 0.000 claims description 34
- 150000003180 prostaglandins Chemical class 0.000 claims description 30
- 230000008018 melting Effects 0.000 claims description 28
- 238000002844 melting Methods 0.000 claims description 28
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 20
- 229920001223 polyethylene glycol Polymers 0.000 claims description 20
- 229920001577 copolymer Polymers 0.000 claims description 16
- 239000002202 Polyethylene glycol Substances 0.000 claims description 13
- 238000010438 heat treatment Methods 0.000 claims description 13
- 239000004626 polylactic acid Substances 0.000 claims description 13
- 230000006870 function Effects 0.000 claims description 12
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims description 12
- 210000000795 conjunctiva Anatomy 0.000 claims description 11
- 210000001525 retina Anatomy 0.000 claims description 11
- GGXICVAJURFBLW-CEYXHVGTSA-N latanoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCC1=CC=CC=C1 GGXICVAJURFBLW-CEYXHVGTSA-N 0.000 claims description 10
- 210000002159 anterior chamber Anatomy 0.000 claims description 8
- 239000011874 heated mixture Substances 0.000 claims description 8
- 239000000155 melt Substances 0.000 claims description 8
- 229940094443 oxytocics prostaglandins Drugs 0.000 claims description 8
- 230000002207 retinal effect Effects 0.000 claims description 8
- 229960001160 latanoprost Drugs 0.000 claims description 7
- MKPLKVHSHYCHOC-AHTXBMBWSA-N travoprost Chemical compound CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\[C@@H](O)COC1=CC=CC(C(F)(F)F)=C1 MKPLKVHSHYCHOC-AHTXBMBWSA-N 0.000 claims description 7
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 claims description 6
- 210000003786 sclera Anatomy 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- 229960002368 travoprost Drugs 0.000 claims description 5
- TVHAZVBUYQMHBC-SNHXEXRGSA-N unoprostone Chemical compound CCCCCCCC(=O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O TVHAZVBUYQMHBC-SNHXEXRGSA-N 0.000 claims description 5
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 claims description 4
- 229960000711 alprostadil Drugs 0.000 claims description 4
- 210000003161 choroid Anatomy 0.000 claims description 4
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 claims description 4
- 208000024304 Choroidal Effusions Diseases 0.000 claims description 3
- 230000001886 ciliary effect Effects 0.000 claims description 3
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 claims description 3
- 229960004317 unoprostone Drugs 0.000 claims description 3
- GVNWZKBFMFUVNX-UHFFFAOYSA-N Adipamide Chemical compound NC(=O)CCCCC(N)=O GVNWZKBFMFUVNX-UHFFFAOYSA-N 0.000 claims description 2
- 239000004698 Polyethylene Substances 0.000 claims description 2
- 229920002367 Polyisobutene Polymers 0.000 claims description 2
- 239000004743 Polypropylene Substances 0.000 claims description 2
- 229960002986 dinoprostone Drugs 0.000 claims description 2
- KAVGMUDTWQVPDF-UHFFFAOYSA-N perflubutane Chemical group FC(F)(F)C(F)(F)C(F)(F)C(F)(F)F KAVGMUDTWQVPDF-UHFFFAOYSA-N 0.000 claims description 2
- 229950003332 perflubutane Drugs 0.000 claims description 2
- 229920000573 polyethylene Polymers 0.000 claims description 2
- 229920001155 polypropylene Polymers 0.000 claims description 2
- STJFYCWYHROASW-UHFFFAOYSA-N O-methyl-glaucamine Natural products CN1CCC2=CC(OC)=C(OC)C=C2C2OC(OC)C3=C4OCOC4=CC=C3C12 STJFYCWYHROASW-UHFFFAOYSA-N 0.000 claims 1
- 230000007704 transition Effects 0.000 claims 1
- 238000001125 extrusion Methods 0.000 abstract description 32
- 210000001508 eye Anatomy 0.000 description 67
- 229940079593 drug Drugs 0.000 description 42
- 230000004410 intraocular pressure Effects 0.000 description 31
- 239000011159 matrix material Substances 0.000 description 29
- 208000024891 symptom Diseases 0.000 description 28
- 239000000463 material Substances 0.000 description 24
- 239000000126 substance Substances 0.000 description 24
- 208000010412 Glaucoma Diseases 0.000 description 23
- 239000006184 cosolvent Substances 0.000 description 22
- 125000004432 carbon atom Chemical group C* 0.000 description 18
- 208000002780 macular degeneration Diseases 0.000 description 17
- 210000001519 tissue Anatomy 0.000 description 16
- 239000006104 solid solution Substances 0.000 description 14
- 239000013543 active substance Substances 0.000 description 13
- 206010064930 age-related macular degeneration Diseases 0.000 description 13
- 239000002245 particle Substances 0.000 description 13
- 239000000843 powder Substances 0.000 description 13
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 12
- 208000017442 Retinal disease Diseases 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 238000009472 formulation Methods 0.000 description 12
- 238000004128 high performance liquid chromatography Methods 0.000 description 11
- 201000010099 disease Diseases 0.000 description 10
- 238000002513 implantation Methods 0.000 description 10
- 238000013268 sustained release Methods 0.000 description 10
- 239000012730 sustained-release form Substances 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 230000001154 acute effect Effects 0.000 description 9
- 125000000217 alkyl group Chemical group 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 8
- 239000002775 capsule Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 206010046851 Uveitis Diseases 0.000 description 7
- 210000005252 bulbus oculi Anatomy 0.000 description 7
- 125000004122 cyclic group Chemical group 0.000 description 7
- 210000000554 iris Anatomy 0.000 description 7
- 239000011859 microparticle Substances 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 239000002220 antihypertensive agent Substances 0.000 description 6
- 230000015556 catabolic process Effects 0.000 description 6
- 238000007906 compression Methods 0.000 description 6
- 238000006731 degradation reaction Methods 0.000 description 6
- 238000012377 drug delivery Methods 0.000 description 6
- 239000004005 microsphere Substances 0.000 description 6
- 208000004644 retinal vein occlusion Diseases 0.000 description 6
- 230000000699 topical effect Effects 0.000 description 6
- 238000009834 vaporization Methods 0.000 description 6
- 230000008016 vaporization Effects 0.000 description 6
- 201000002862 Angle-Closure Glaucoma Diseases 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 206010038923 Retinopathy Diseases 0.000 description 5
- 210000001742 aqueous humor Anatomy 0.000 description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 230000006835 compression Effects 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 230000003628 erosive effect Effects 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 229940112534 lumigan Drugs 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 229920001610 polycaprolactone Polymers 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 208000011580 syndromic disease Diseases 0.000 description 5
- 235000012431 wafers Nutrition 0.000 description 5
- 239000003643 water by type Substances 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 206010012689 Diabetic retinopathy Diseases 0.000 description 4
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
- 208000001344 Macular Edema Diseases 0.000 description 4
- 229920002562 Polyethylene Glycol 3350 Polymers 0.000 description 4
- 201000007527 Retinal artery occlusion Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 125000003545 alkoxy group Chemical group 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 229940127088 antihypertensive drug Drugs 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- 229960000686 benzalkonium chloride Drugs 0.000 description 4
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 125000000753 cycloalkyl group Chemical group 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 208000027993 eye symptom Diseases 0.000 description 4
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 4
- 125000001072 heteroaryl group Chemical group 0.000 description 4
- 229920001519 homopolymer Polymers 0.000 description 4
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 239000004310 lactic acid Substances 0.000 description 4
- 235000014655 lactic acid Nutrition 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 239000004632 polycaprolactone Substances 0.000 description 4
- 229920002959 polymer blend Polymers 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical group OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 208000002177 Cataract Diseases 0.000 description 3
- 208000031886 HIV Infections Diseases 0.000 description 3
- 208000037357 HIV infectious disease Diseases 0.000 description 3
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 3
- 206010025415 Macular oedema Diseases 0.000 description 3
- 206010030348 Open-Angle Glaucoma Diseases 0.000 description 3
- 201000007737 Retinal degeneration Diseases 0.000 description 3
- 206010038848 Retinal detachment Diseases 0.000 description 3
- 206010038910 Retinitis Diseases 0.000 description 3
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 201000001326 acute closed-angle glaucoma Diseases 0.000 description 3
- 125000005157 alkyl carboxy group Chemical group 0.000 description 3
- 239000002876 beta blocker Substances 0.000 description 3
- 229940097320 beta blocking agent Drugs 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 201000005667 central retinal vein occlusion Diseases 0.000 description 3
- 201000005682 chronic closed-angle glaucoma Diseases 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000013270 controlled release Methods 0.000 description 3
- 210000004087 cornea Anatomy 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 208000030533 eye disease Diseases 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 3
- 150000002430 hydrocarbons Chemical class 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 201000010230 macular retinal edema Diseases 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- XBGNERSKEKDZDS-UHFFFAOYSA-N n-[2-(dimethylamino)ethyl]acridine-4-carboxamide Chemical compound C1=CC=C2N=C3C(C(=O)NCCN(C)C)=CC=CC3=CC2=C1 XBGNERSKEKDZDS-UHFFFAOYSA-N 0.000 description 3
- 230000000324 neuroprotective effect Effects 0.000 description 3
- 210000001328 optic nerve Anatomy 0.000 description 3
- 229920002451 polyvinyl alcohol Polymers 0.000 description 3
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 230000004264 retinal detachment Effects 0.000 description 3
- 229910001220 stainless steel Inorganic materials 0.000 description 3
- 239000010935 stainless steel Substances 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 230000008733 trauma Effects 0.000 description 3
- TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 description 2
- 229920003178 (lactide-co-glycolide) polymer Polymers 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- JJTUDXZGHPGLLC-IMJSIDKUSA-N 4511-42-6 Chemical compound C[C@@H]1OC(=O)[C@H](C)OC1=O JJTUDXZGHPGLLC-IMJSIDKUSA-N 0.000 description 2
- 208000009137 Behcet syndrome Diseases 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 2
- 208000014882 Carotid artery disease Diseases 0.000 description 2
- 208000005590 Choroidal Neovascularization Diseases 0.000 description 2
- 206010060823 Choroidal neovascularisation Diseases 0.000 description 2
- 208000002691 Choroiditis Diseases 0.000 description 2
- 206010010741 Conjunctivitis Diseases 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- 206010012688 Diabetic retinal oedema Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 102100022258 Disks large homolog 5 Human genes 0.000 description 2
- 208000020564 Eye injury Diseases 0.000 description 2
- 201000002563 Histoplasmosis Diseases 0.000 description 2
- 101100063489 Homo sapiens DLG5 gene Proteins 0.000 description 2
- 206010020565 Hyperaemia Diseases 0.000 description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000010164 Multifocal Choroiditis Diseases 0.000 description 2
- 206010030043 Ocular hypertension Diseases 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 229920001244 Poly(D,L-lactide) Polymers 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 208000003971 Posterior uveitis Diseases 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 206010064714 Radiation retinopathy Diseases 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 201000005485 Toxoplasmosis Diseases 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 125000002015 acyclic group Chemical group 0.000 description 2
- 239000000674 adrenergic antagonist Substances 0.000 description 2
- 125000004450 alkenylene group Chemical group 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 229940125715 antihistaminic agent Drugs 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 229940072107 ascorbate Drugs 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 2
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000003489 carbonate dehydratase inhibitor Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 229960002588 cefradine Drugs 0.000 description 2
- RDLPVSKMFDYCOR-UEKVPHQBSA-N cephradine Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CCC=CC1 RDLPVSKMFDYCOR-UEKVPHQBSA-N 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 239000000599 controlled substance Substances 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- 201000011190 diabetic macular edema Diseases 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 238000007907 direct compression Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- IAVUPMFITXYVAF-XPUUQOCRSA-N dorzolamide Chemical compound CCN[C@H]1C[C@H](C)S(=O)(=O)C2=C1C=C(S(N)(=O)=O)S2 IAVUPMFITXYVAF-XPUUQOCRSA-N 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
- 229960005420 etoposide Drugs 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 229940012356 eye drops Drugs 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 201000006321 fundus dystrophy Diseases 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000009477 glass transition Effects 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 239000008240 homogeneous mixture Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 229960004716 idoxuridine Drugs 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 229940124589 immunosuppressive drug Drugs 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000004570 mortar (masonry) Substances 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 125000004043 oxo group Chemical group O=* 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000002831 pharmacologic agent Substances 0.000 description 2
- ZJAOAACCNHFJAH-UHFFFAOYSA-N phosphonoformic acid Chemical compound OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 description 2
- 230000000649 photocoagulation Effects 0.000 description 2
- 238000002428 photodynamic therapy Methods 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920000570 polyether Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 229960004618 prednisone Drugs 0.000 description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 201000007914 proliferative diabetic retinopathy Diseases 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 210000001747 pupil Anatomy 0.000 description 2
- 230000004258 retinal degeneration Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007962 solid dispersion Substances 0.000 description 2
- 230000007928 solubilization Effects 0.000 description 2
- 238000005063 solubilization Methods 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 208000006379 syphilis Diseases 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 229960004605 timolol Drugs 0.000 description 2
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 2
- 230000004393 visual impairment Effects 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 229920003169 water-soluble polymer Polymers 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- WMBWREPUVVBILR-WIYYLYMNSA-N (-)-Epigallocatechin-3-o-gallate Chemical compound O([C@@H]1CC2=C(O)C=C(C=C2O[C@@H]1C=1C=C(O)C(O)=C(O)C=1)O)C(=O)C1=CC(O)=C(O)C(O)=C1 WMBWREPUVVBILR-WIYYLYMNSA-N 0.000 description 1
- DMASLKHVQRHNES-UPOGUZCLSA-N (3R)-beta,beta-caroten-3-ol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C DMASLKHVQRHNES-UPOGUZCLSA-N 0.000 description 1
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 description 1
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 1
- 125000006724 (C1-C5) alkyl ester group Chemical group 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 description 1
- IZFHEQBZOYJLPK-SSDOTTSWSA-N (R)-dihydrolipoic acid Chemical compound OC(=O)CCCC[C@@H](S)CCS IZFHEQBZOYJLPK-SSDOTTSWSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UWTATZPHSA-M (R)-lactate Chemical compound C[C@@H](O)C([O-])=O JVTAAEKCZFNVCJ-UWTATZPHSA-M 0.000 description 1
- JCIIKRHCWVHVFF-UHFFFAOYSA-N 1,2,4-thiadiazol-5-amine;hydrochloride Chemical compound Cl.NC1=NC=NS1 JCIIKRHCWVHVFF-UHFFFAOYSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- SPCKHVPPRJWQRZ-UHFFFAOYSA-N 2-benzhydryloxy-n,n-dimethylethanamine;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 SPCKHVPPRJWQRZ-UHFFFAOYSA-N 0.000 description 1
- SGUAFYQXFOLMHL-UHFFFAOYSA-N 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide Chemical compound C=1C=C(O)C(C(N)=O)=CC=1C(O)CNC(C)CCC1=CC=CC=C1 SGUAFYQXFOLMHL-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000004142 Acute Retinal Necrosis Syndrome Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- WZPBZJONDBGPKJ-UHFFFAOYSA-N Antibiotic SQ 26917 Natural products O=C1N(S(O)(=O)=O)C(C)C1NC(=O)C(=NOC(C)(C)C(O)=O)C1=CSC(N)=N1 WZPBZJONDBGPKJ-UHFFFAOYSA-N 0.000 description 1
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- FVLVBPDQNARYJU-XAHDHGMMSA-N C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O Chemical compound C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O FVLVBPDQNARYJU-XAHDHGMMSA-N 0.000 description 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 229940122072 Carbonic anhydrase inhibitor Drugs 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 description 1
- 108010087806 Carnosine Proteins 0.000 description 1
- UQLLWWBDSUHNEB-CZUORRHYSA-N Cefaprin Chemical compound N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C(O)=O)C(=O)CSC1=CC=NC=C1 UQLLWWBDSUHNEB-CZUORRHYSA-N 0.000 description 1
- GNWUOVJNSFPWDD-XMZRARIVSA-M Cefoxitin sodium Chemical compound [Na+].N([C@]1(OC)C(N2C(=C(COC(N)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)CC1=CC=CS1 GNWUOVJNSFPWDD-XMZRARIVSA-M 0.000 description 1
- 208000003569 Central serous chorioretinopathy Diseases 0.000 description 1
- 206010070957 Choroidal haemangioma Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 description 1
- 208000021089 Coats disease Diseases 0.000 description 1
- 108010078777 Colistin Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 206010018325 Congenital glaucomas Diseases 0.000 description 1
- 206010010559 Congenital night blindness Diseases 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 239000004212 Cryptoxanthin Substances 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 206010058202 Cystoid macular oedema Diseases 0.000 description 1
- 229930182843 D-Lactic acid Natural products 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UWTATZPHSA-N D-lactic acid Chemical compound C[C@@H](O)C(O)=O JVTAAEKCZFNVCJ-UWTATZPHSA-N 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 206010012565 Developmental glaucoma Diseases 0.000 description 1
- 206010012692 Diabetic uveitis Diseases 0.000 description 1
- 208000019878 Eales disease Diseases 0.000 description 1
- 208000001351 Epiretinal Membrane Diseases 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- 208000029728 Eyelid disease Diseases 0.000 description 1
- 208000028506 Familial Exudative Vitreoretinopathies Diseases 0.000 description 1
- UUOUOERPONYGOS-CLCRDYEYSA-N Fluocinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3C[C@H](F)C2=C1 UUOUOERPONYGOS-CLCRDYEYSA-N 0.000 description 1
- WJOHZNCJWYWUJD-IUGZLZTKSA-N Fluocinonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O WJOHZNCJWYWUJD-IUGZLZTKSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 235000011201 Ginkgo Nutrition 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000228402 Histoplasma Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010058558 Hypoperfusion Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical class C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 208000032578 Inherited retinal disease Diseases 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 206010022557 Intermediate uveitis Diseases 0.000 description 1
- 206010022941 Iridocyclitis Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- RITKHVBHSGLULN-WHFBIAKZSA-N L-gamma-glutamyl-L-cysteine Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(O)=O RITKHVBHSGLULN-WHFBIAKZSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 208000011671 Lacrimal disease Diseases 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- 208000031471 Macular fibrosis Diseases 0.000 description 1
- 208000035719 Maculopathy Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
- IJHNSHDBIRRJRN-UHFFFAOYSA-N N,N-dimethyl-3-phenyl-3-(2-pyridinyl)-1-propanamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=CC=C1 IJHNSHDBIRRJRN-UHFFFAOYSA-N 0.000 description 1
- SBKRTALNRRAOJP-BWSIXKJUSA-N N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methylheptanamide (6S)-N-[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-4-amino-1-oxo-1-[[(3S,6S,9S,12S,15R,18R,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1-oxobutan-2-yl]-6-methyloctanamide sulfuric acid Polymers OS(O)(=O)=O.CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O.CC[C@H](C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)[C@@H](CCN)NC1=O)[C@@H](C)O SBKRTALNRRAOJP-BWSIXKJUSA-N 0.000 description 1
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 206010068960 Narrow anterior chamber angle Diseases 0.000 description 1
- 206010065119 Necrotising herpetic retinopathy Diseases 0.000 description 1
- 206010069385 Ocular ischaemic syndrome Diseases 0.000 description 1
- 206010065700 Ocular sarcoidosis Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241001420836 Ophthalmitis Species 0.000 description 1
- 208000003435 Optic Neuritis Diseases 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- 208000034530 PLAA-associated neurodevelopmental disease Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 208000034247 Pattern dystrophy Diseases 0.000 description 1
- ISFHAYSTHMVOJR-UHFFFAOYSA-N Phenindamine Chemical compound C1N(C)CCC(C2=CC=CC=C22)=C1C2C1=CC=CC=C1 ISFHAYSTHMVOJR-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229920006022 Poly(L-lactide-co-glycolide)-b-poly(ethylene glycol) Polymers 0.000 description 1
- 229920002535 Polyethylene Glycol 1500 Polymers 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 229920002582 Polyethylene Glycol 600 Polymers 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 108010093965 Polymyxin B Proteins 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 description 1
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 1
- 208000002367 Retinal Perforations Diseases 0.000 description 1
- 208000008709 Retinal Telangiectasis Diseases 0.000 description 1
- 208000032430 Retinal dystrophy Diseases 0.000 description 1
- 206010038899 Retinal telangiectasia Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 206010038934 Retinopathy proliferative Diseases 0.000 description 1
- 206010038935 Retinopathy sickle cell Diseases 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 206010039705 Scleritis Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- UIRKNQLZZXALBI-MSVGPLKSSA-N Squalamine Chemical compound C([C@@H]1C[C@H]2O)[C@@H](NCCCNCCCCN)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@H](C(C)C)OS(O)(=O)=O)[C@@]2(C)CC1 UIRKNQLZZXALBI-MSVGPLKSSA-N 0.000 description 1
- UIRKNQLZZXALBI-UHFFFAOYSA-N Squalamine Natural products OC1CC2CC(NCCCNCCCCN)CCC2(C)C2C1C1CCC(C(C)CCC(C(C)C)OS(O)(=O)=O)C1(C)CC2 UIRKNQLZZXALBI-UHFFFAOYSA-N 0.000 description 1
- 208000027073 Stargardt disease Diseases 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 208000004350 Strabismus Diseases 0.000 description 1
- 208000036038 Subretinal fibrosis Diseases 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 206010042742 Sympathetic ophthalmia Diseases 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 206010044269 Toxocariasis Diseases 0.000 description 1
- UFLGIAIHIAPJJC-UHFFFAOYSA-N Tripelennamine Chemical compound C=1C=CC=NC=1N(CCN(C)C)CC1=CC=CC=C1 UFLGIAIHIAPJJC-UHFFFAOYSA-N 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 208000001445 Uveomeningoencephalitic Syndrome Diseases 0.000 description 1
- HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 description 1
- 238000005411 Van der Waals force Methods 0.000 description 1
- 108010059993 Vancomycin Proteins 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 208000034705 Vogt-Koyanagi-Harada syndrome Diseases 0.000 description 1
- 208000029977 White Dot Syndromes Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 201000001408 X-linked juvenile retinoschisis 1 Diseases 0.000 description 1
- 208000017441 X-linked retinoschisis Diseases 0.000 description 1
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 description 1
- WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 1
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- GOEMGAFJFRBGGG-UHFFFAOYSA-N acebutolol Chemical compound CCCC(=O)NC1=CC=C(OCC(O)CNC(C)C)C(C(C)=O)=C1 GOEMGAFJFRBGGG-UHFFFAOYSA-N 0.000 description 1
- 229960002122 acebutolol Drugs 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- APYDIYHMJJUSAT-UHFFFAOYSA-N acetic acid;n,n-diethylethanamine;methanol Chemical compound OC.CC(O)=O.CCN(CC)CC APYDIYHMJJUSAT-UHFFFAOYSA-N 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 229930183665 actinomycin Natural products 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000048 adrenergic agonist Substances 0.000 description 1
- 239000000695 adrenergic alpha-agonist Substances 0.000 description 1
- 229940126157 adrenergic receptor agonist Drugs 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 102000030484 alpha-2 Adrenergic Receptor Human genes 0.000 description 1
- 108020004101 alpha-2 Adrenergic Receptor Proteins 0.000 description 1
- WOLHOYHSEKDWQH-UHFFFAOYSA-N amantadine hydrochloride Chemical compound [Cl-].C1C(C2)CC3CC2CC1([NH3+])C3 WOLHOYHSEKDWQH-UHFFFAOYSA-N 0.000 description 1
- 229960001280 amantadine hydrochloride Drugs 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 201000004612 anterior uveitis Diseases 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- 239000000921 anthelmintic agent Substances 0.000 description 1
- 229940124339 anthelmintic agent Drugs 0.000 description 1
- 230000001384 anti-glaucoma Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 229940006133 antiglaucoma drug and miotics carbonic anhydrase inhibitors Drugs 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 235000013793 astaxanthin Nutrition 0.000 description 1
- 239000001168 astaxanthin Substances 0.000 description 1
- 229940022405 astaxanthin Drugs 0.000 description 1
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 description 1
- 201000009310 astigmatism Diseases 0.000 description 1
- 229960002274 atenolol Drugs 0.000 description 1
- 229940098164 augmentin Drugs 0.000 description 1
- 239000005441 aurora Substances 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 229960000383 azatadine Drugs 0.000 description 1
- SEBMTIQKRHYNIT-UHFFFAOYSA-N azatadine Chemical compound C1CN(C)CCC1=C1C2=NC=CC=C2CCC2=CC=CC=C21 SEBMTIQKRHYNIT-UHFFFAOYSA-N 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- 229960003644 aztreonam Drugs 0.000 description 1
- WZPBZJONDBGPKJ-VEHQQRBSSA-N aztreonam Chemical compound O=C1N(S([O-])(=O)=O)[C@@H](C)[C@@H]1NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC([NH3+])=N1 WZPBZJONDBGPKJ-VEHQQRBSSA-N 0.000 description 1
- 229960002699 bacampicillin Drugs 0.000 description 1
- PFOLLRNADZZWEX-FFGRCDKISA-N bacampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)[C@H](C(S3)(C)C)C(=O)OC(C)OC(=O)OCC)=CC=CC=C1 PFOLLRNADZZWEX-FFGRCDKISA-N 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 235000002360 beta-cryptoxanthin Nutrition 0.000 description 1
- DMASLKHVQRHNES-ITUXNECMSA-N beta-cryptoxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CCCC2(C)C DMASLKHVQRHNES-ITUXNECMSA-N 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 229940102480 bilberry extract Drugs 0.000 description 1
- 235000019209 bilberry extract Nutrition 0.000 description 1
- 229940006072 bimatoprost ophthalmic solution Drugs 0.000 description 1
- 229920000229 biodegradable polyester Polymers 0.000 description 1
- 239000004622 biodegradable polyester Substances 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 206010072959 birdshot chorioretinopathy Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 206010005159 blepharospasm Diseases 0.000 description 1
- 230000000744 blepharospasm Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 150000001642 boronic acid derivatives Chemical class 0.000 description 1
- 229960000725 brompheniramine Drugs 0.000 description 1
- ZDIGNSYAACHWNL-UHFFFAOYSA-N brompheniramine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Br)C=C1 ZDIGNSYAACHWNL-UHFFFAOYSA-N 0.000 description 1
- 239000000648 calcium alginate Substances 0.000 description 1
- 235000010410 calcium alginate Nutrition 0.000 description 1
- 229960002681 calcium alginate Drugs 0.000 description 1
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 229940127093 camptothecin Drugs 0.000 description 1
- 229960000428 carbinoxamine Drugs 0.000 description 1
- OJFSXZCBGQGRNV-UHFFFAOYSA-N carbinoxamine Chemical compound C=1C=CC=NC=1C(OCCN(C)C)C1=CC=C(Cl)C=C1 OJFSXZCBGQGRNV-UHFFFAOYSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 description 1
- 229940044199 carnosine Drugs 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 229960005361 cefaclor Drugs 0.000 description 1
- QYIYFLOTGYLRGG-GPCCPHFNSA-N cefaclor Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 QYIYFLOTGYLRGG-GPCCPHFNSA-N 0.000 description 1
- 229960000603 cefalotin Drugs 0.000 description 1
- 229960004350 cefapirin Drugs 0.000 description 1
- 229960001139 cefazolin Drugs 0.000 description 1
- MLYYVTUWGNIJIB-BXKDBHETSA-N cefazolin Chemical compound S1C(C)=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CN3N=NN=C3)[C@H]2SC1 MLYYVTUWGNIJIB-BXKDBHETSA-N 0.000 description 1
- 229960004682 cefoperazone Drugs 0.000 description 1
- GCFBRXLSHGKWDP-XCGNWRKASA-N cefoperazone Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 GCFBRXLSHGKWDP-XCGNWRKASA-N 0.000 description 1
- 229960004292 ceforanide Drugs 0.000 description 1
- SLAYUXIURFNXPG-CRAIPNDOSA-N ceforanide Chemical compound NCC1=CC=CC=C1CC(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)CC(O)=O)CS[C@@H]21 SLAYUXIURFNXPG-CRAIPNDOSA-N 0.000 description 1
- 229960004261 cefotaxime Drugs 0.000 description 1
- AZZMGZXNTDTSME-JUZDKLSSSA-M cefotaxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 AZZMGZXNTDTSME-JUZDKLSSSA-M 0.000 description 1
- 229960005495 cefotetan Drugs 0.000 description 1
- SRZNHPXWXCNNDU-RHBCBLIFSA-N cefotetan Chemical compound N([C@]1(OC)C(N2C(=C(CSC=3N(N=NN=3)C)CS[C@@H]21)C(O)=O)=O)C(=O)C1SC(=C(C(N)=O)C(O)=O)S1 SRZNHPXWXCNNDU-RHBCBLIFSA-N 0.000 description 1
- 229960002682 cefoxitin Drugs 0.000 description 1
- 229960000484 ceftazidime Drugs 0.000 description 1
- NMVPEQXCMGEDNH-TZVUEUGBSA-N ceftazidime pentahydrate Chemical compound O.O.O.O.O.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC(C)(C)C(O)=O)C=2N=C(N)SC=2)CC=1C[N+]1=CC=CC=C1 NMVPEQXCMGEDNH-TZVUEUGBSA-N 0.000 description 1
- 229960001991 ceftizoxime Drugs 0.000 description 1
- NNULBSISHYWZJU-LLKWHZGFSA-N ceftizoxime Chemical compound N([C@@H]1C(N2C(=CCS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 NNULBSISHYWZJU-LLKWHZGFSA-N 0.000 description 1
- 229960004755 ceftriaxone Drugs 0.000 description 1
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 1
- 229960001668 cefuroxime Drugs 0.000 description 1
- JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 201000005849 central retinal artery occlusion Diseases 0.000 description 1
- 229940106164 cephalexin Drugs 0.000 description 1
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 1
- VUFGUVLLDPOSBC-XRZFDKQNSA-M cephalothin sodium Chemical compound [Na+].N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C([O-])=O)C(=O)CC1=CC=CS1 VUFGUVLLDPOSBC-XRZFDKQNSA-M 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 229960003291 chlorphenamine Drugs 0.000 description 1
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 description 1
- 208000027129 choroid disease Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 210000004240 ciliary body Anatomy 0.000 description 1
- 229960001229 ciprofloxacin hydrochloride Drugs 0.000 description 1
- DIOIOSKKIYDRIQ-UHFFFAOYSA-N ciprofloxacin hydrochloride Chemical compound Cl.C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 DIOIOSKKIYDRIQ-UHFFFAOYSA-N 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 229960002881 clemastine Drugs 0.000 description 1
- YNNUSGIPVFPVBX-NHCUHLMSSA-N clemastine Chemical compound CN1CCC[C@@H]1CCO[C@@](C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 YNNUSGIPVFPVBX-NHCUHLMSSA-N 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 229960003326 cloxacillin Drugs 0.000 description 1
- LQOLIRLGBULYKD-JKIFEVAISA-N cloxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl LQOLIRLGBULYKD-JKIFEVAISA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229960003346 colistin Drugs 0.000 description 1
- 208000020656 combined hamartoma of the retina and retinal pigment epithelium Diseases 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 208000021921 corneal disease Diseases 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 235000019244 cryptoxanthin Nutrition 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 229960004244 cyclacillin Drugs 0.000 description 1
- HGBLNBBNRORJKI-WCABBAIRSA-N cyclacillin Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)C1(N)CCCCC1 HGBLNBBNRORJKI-WCABBAIRSA-N 0.000 description 1
- LPIQUOYDBNQMRZ-UHFFFAOYSA-N cyclopentene Chemical compound C1CC=CC1 LPIQUOYDBNQMRZ-UHFFFAOYSA-N 0.000 description 1
- 229930182912 cyclosporin Natural products 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 201000010206 cystoid macular edema Diseases 0.000 description 1
- 229940022769 d- lactic acid Drugs 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960002691 dexbrompheniramine Drugs 0.000 description 1
- ZDIGNSYAACHWNL-HNNXBMFYSA-N dexbrompheniramine Chemical compound C1([C@H](CCN(C)C)C=2N=CC=CC=2)=CC=C(Br)C=C1 ZDIGNSYAACHWNL-HNNXBMFYSA-N 0.000 description 1
- 229960001882 dexchlorpheniramine Drugs 0.000 description 1
- SOYKEARSMXGVTM-HNNXBMFYSA-N dexchlorpheniramine Chemical compound C1([C@H](CCN(C)C)C=2N=CC=CC=2)=CC=C(Cl)C=C1 SOYKEARSMXGVTM-HNNXBMFYSA-N 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 229940061607 dibasic sodium phosphate Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229960000520 diphenhydramine Drugs 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 208000009190 disseminated intravascular coagulation Diseases 0.000 description 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
- 229960003933 dorzolamide Drugs 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- 229960005178 doxylamine Drugs 0.000 description 1
- HCFDWZZGGLSKEP-UHFFFAOYSA-N doxylamine Chemical compound C=1C=CC=NC=1C(C)(OCCN(C)C)C1=CC=CC=C1 HCFDWZZGGLSKEP-UHFFFAOYSA-N 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000009506 drug dissolution testing Methods 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000004406 elevated intraocular pressure Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 206010014801 endophthalmitis Diseases 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 201000006902 exudative vitreoretinopathy Diseases 0.000 description 1
- 208000024519 eye neoplasm Diseases 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229950002335 fluazacort Drugs 0.000 description 1
- BYZCJOHDXLROEC-RBWIMXSLSA-N fluazacort Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)=N[C@@]3(C(=O)COC(=O)C)[C@@]1(C)C[C@@H]2O BYZCJOHDXLROEC-RBWIMXSLSA-N 0.000 description 1
- 229940043075 fluocinolone Drugs 0.000 description 1
- 229960000785 fluocinonide Drugs 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- 229960005102 foscarnet Drugs 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 108010068906 gamma-glutamylcysteine Proteins 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
- 229910002804 graphite Inorganic materials 0.000 description 1
- 239000010439 graphite Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- AKRQHOWXVSDJEF-UHFFFAOYSA-N heptane-1-sulfonic acid Chemical class CCCCCCCS(O)(=O)=O AKRQHOWXVSDJEF-UHFFFAOYSA-N 0.000 description 1
- 201000007500 hereditary night blindness Diseases 0.000 description 1
- 125000004404 heteroalkyl group Chemical group 0.000 description 1
- 239000007970 homogeneous dispersion Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229960000930 hydroxyzine Drugs 0.000 description 1
- ZQDWXGKKHFNSQK-UHFFFAOYSA-N hydroxyzine Chemical compound C1CN(CCOCCO)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZQDWXGKKHFNSQK-UHFFFAOYSA-N 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000007925 in vitro drug release testing Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 208000017532 inherited retinal dystrophy Diseases 0.000 description 1
- 238000001746 injection moulding Methods 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 229940116871 l-lactate Drugs 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 229960001632 labetalol Drugs 0.000 description 1
- 150000003893 lactate salts Chemical class 0.000 description 1
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 229940125722 laxative agent Drugs 0.000 description 1
- 229960005287 lincomycin Drugs 0.000 description 1
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- 229960001798 loteprednol Drugs 0.000 description 1
- YPZVAYHNBBHPTO-MXRBDKCISA-N loteprednol Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)OCCl)[C@@H]4[C@@H]3CCC2=C1 YPZVAYHNBBHPTO-MXRBDKCISA-N 0.000 description 1
- 235000012680 lutein Nutrition 0.000 description 1
- 239000001656 lutein Substances 0.000 description 1
- 229960005375 lutein Drugs 0.000 description 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- 208000019420 lymphoid neoplasm Diseases 0.000 description 1
- 208000038015 macular disease Diseases 0.000 description 1
- 208000029233 macular holes Diseases 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229960000582 mepyramine Drugs 0.000 description 1
- YECBIJXISLIIDS-UHFFFAOYSA-N mepyramine Chemical compound C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 YECBIJXISLIIDS-UHFFFAOYSA-N 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 229960004584 methylprednisolone Drugs 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 208000001491 myopia Diseases 0.000 description 1
- 230000004379 myopia Effects 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- JORAUNFTUVJTNG-BSTBCYLQSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O JORAUNFTUVJTNG-BSTBCYLQSA-N 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N n-hexadecanoic acid Natural products CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 239000004090 neuroprotective agent Substances 0.000 description 1
- 201000002165 neuroretinitis Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 201000005111 ocular hyperemia Diseases 0.000 description 1
- 208000008940 ocular tuberculosis Diseases 0.000 description 1
- 239000002997 ophthalmic solution Substances 0.000 description 1
- 208000020911 optic nerve disease Diseases 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 150000002905 orthoesters Chemical class 0.000 description 1
- 208000008798 osteoma Diseases 0.000 description 1
- 229960001019 oxacillin Drugs 0.000 description 1
- UWYHMGVUTGAWSP-JKIFEVAISA-N oxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 208000010403 panophthalmitis Diseases 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000005453 pelletization Methods 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 229940090663 penicillin v potassium Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960003534 phenindamine Drugs 0.000 description 1
- 229960001190 pheniramine Drugs 0.000 description 1
- HCTVWSOKIJULET-LQDWTQKMSA-M phenoxymethylpenicillin potassium Chemical compound [K+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)COC1=CC=CC=C1 HCTVWSOKIJULET-LQDWTQKMSA-M 0.000 description 1
- 229940096826 phenylmercuric acetate Drugs 0.000 description 1
- VUXSPDNLYQTOSY-UHFFFAOYSA-N phenylmercuric borate Chemical compound OB(O)O[Hg]C1=CC=CC=C1 VUXSPDNLYQTOSY-UHFFFAOYSA-N 0.000 description 1
- 229960000247 phenylmercuric borate Drugs 0.000 description 1
- PDTFCHSETJBPTR-UHFFFAOYSA-N phenylmercuric nitrate Chemical compound [O-][N+](=O)O[Hg]C1=CC=CC=C1 PDTFCHSETJBPTR-UHFFFAOYSA-N 0.000 description 1
- 208000001297 phlebitis Diseases 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229960002292 piperacillin Drugs 0.000 description 1
- WCMIIGXFCMNQDS-IDYPWDAWSA-M piperacillin sodium Chemical compound [Na+].O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C([O-])=O)C(C)(C)S[C@@H]21 WCMIIGXFCMNQDS-IDYPWDAWSA-M 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920000151 polyglycol Polymers 0.000 description 1
- 239000010695 polyglycol Substances 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- XDJYMJULXQKGMM-UHFFFAOYSA-N polymyxin E1 Natural products CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O XDJYMJULXQKGMM-UHFFFAOYSA-N 0.000 description 1
- KNIWPHSUTGNZST-UHFFFAOYSA-N polymyxin E2 Natural products CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O KNIWPHSUTGNZST-UHFFFAOYSA-N 0.000 description 1
- 229960003548 polymyxin b sulfate Drugs 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 201000002267 posterior uveal melanoma Diseases 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 201000010041 presbyopia Diseases 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000006785 proliferative vitreoretinopathy Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 150000003165 prostaglandin E1 derivatives Chemical class 0.000 description 1
- 150000003166 prostaglandin E2 derivatives Chemical class 0.000 description 1
- 150000003169 prostaglandin F2α derivatives Chemical class 0.000 description 1
- 208000022749 pupil disease Diseases 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 208000014733 refractive error Diseases 0.000 description 1
- 238000012429 release testing Methods 0.000 description 1
- 210000001927 retinal artery Anatomy 0.000 description 1
- 230000004283 retinal dysfunction Effects 0.000 description 1
- 239000000790 retinal pigment Substances 0.000 description 1
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 1
- 201000007714 retinoschisis Diseases 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 229960003440 semustine Drugs 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000002884 skin cream Substances 0.000 description 1
- 239000011734 sodium Chemical class 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 229940100996 sodium bisulfate Drugs 0.000 description 1
- 229940001607 sodium bisulfite Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 229940001474 sodium thiosulfate Drugs 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 229950001248 squalamine Drugs 0.000 description 1
- 239000012899 standard injection Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical class OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229960005404 sulfamethoxazole Drugs 0.000 description 1
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 1
- 238000013269 sustained drug release Methods 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 229960001967 tacrolimus Drugs 0.000 description 1
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229940063683 taxotere Drugs 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- VUYXVWGKCKTUMF-UHFFFAOYSA-N tetratriacontaethylene glycol monomethyl ether Chemical compound COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO VUYXVWGKCKTUMF-UHFFFAOYSA-N 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000002076 thermal analysis method Methods 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000001585 trabecular meshwork Anatomy 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 229960005294 triamcinolone Drugs 0.000 description 1
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 229960001082 trimethoprim Drugs 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- 229960003223 tripelennamine Drugs 0.000 description 1
- 229960001128 triprolidine Drugs 0.000 description 1
- CBEQULMOCCWAQT-WOJGMQOQSA-N triprolidine Chemical compound C1=CC(C)=CC=C1C(\C=1N=CC=CC=1)=C/CN1CCCC1 CBEQULMOCCWAQT-WOJGMQOQSA-N 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229940108420 trusopt Drugs 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229960004441 tyrosine Drugs 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 229960003165 vancomycin Drugs 0.000 description 1
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 229920003176 water-insoluble polymer Polymers 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 229940002639 xalatan Drugs 0.000 description 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 1
- 229960000523 zalcitabine Drugs 0.000 description 1
- 235000010930 zeaxanthin Nutrition 0.000 description 1
- 239000001775 zeaxanthin Substances 0.000 description 1
- 229940043269 zeaxanthin Drugs 0.000 description 1
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1
- 229960002555 zidovudine Drugs 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
- Prostheses (AREA)
Abstract
Description
物質の溶解度パラメーターは、その物質の相対溶解挙動を示す数値である。溶解度パラメーターは、物質の凝集エネルギー密度から導き出され、次に、これは気化熱から導き出される。物質の気化熱は、物質を気化させる(気体にする)のに必要とされるエネルギーである。気化熱(液体物質1立方メートル当たりのカロリー)から、凝集エネルギー密度(c)を導き出すことができる:
液体の凝集エネルギー密度(c)は、気化エネルギー(1立方センチメートル当たりのカロリー)を示す数値であり、液体分子を結合させるファンデルワールス力の程度の鏡面反射である。2つの物質の溶解性は、それらの分子間引力が同様である場合にのみ可能であり、同様の凝集エネルギー密度値を有する物質は、互いに混和性である。
本発明は、眼内インプラントの低温製造法を含む。該方法は、環状脂質治療薬およびポリマーを組み合わせて混合物を形成することによって行われる。次に、混合物を約50℃〜約80℃の温度に加熱し、次に、加熱混合物を押し出し、それによって眼内使用に適したインプラントを製造する。「低温」法とは、約50℃〜約80℃の温度で行われる方法を意味する。この方法によって製造されたインプラントは眼内インプラントであり、これは、インプラントが、眼組織内または眼腔または実質的な眼腔内への挿入または埋め込みに好適な構造にされ形状にされていることを意味する。従って、本発明の方法によって製造されるインプラントは、例えば、下記の位置への挿入または埋め込みに好適である:前房、後房、硝子体腔、脈絡膜、脈絡膜上腔、網膜下腔、結膜、結膜下腔、強膜外隙、角膜内腔、角膜上腔、強膜、毛様体輪、外科的誘発無血管領域、網膜黄斑、網膜およびテノン下位置。好ましくは、インプラントが抗高圧治療薬(例えば、プロスタグランジン類似体、α-アドレナリン受容体作用薬またはβ-遮断薬)を含有する場合、インプラントを結膜下に埋め込むかまたは挿入し、それによって、抗高圧治療薬の標的組織である毛様体に近接した位置に配置する。
ポリマー 溶解度パラメーター(δ)
デカフルオロブタン 10.6
ポリ(イソブチレン) 16.2
ポリ(ヘキセメチレンアジパミド) 13.6
ポリプロピレン 18.0
ポリエチレン 18.1
ポリビニルクロリド 21.4
ならびに、約80℃未満の軟化点および約12〜約28(MPa)1/2の溶解度パラメーターを有する他の低分子量ポリマー、ワックスおよび長鎖炭化水素。
(a) 下記の成分を合わして、混合物を形成する工程:
(i) プロスタグランジン類似体であって、インプラントの約5wt%〜約30wt%(かつ70wt%までも)を占めるプロスタグランジン類似体;
(ii) ポリ(ラクチド-コ-グリコリド)コポリマーであって、インプラントの約30wt%〜約90wt%を占めるポリ(ラクチド-コ-グリコリド)コポリマー;
(ii) 第二生分解性ポリマーであって、インプラントの約5wt%〜約40wt%を占める第二生分解性ポリマー;
ここで、
(α) ポリ(ラクチド-コ-グリコリド)コポリマーおよび第二生分解性ポリマーは、異なるポリマーであり;
(β) プロスタグランジン類似体、ポリ(ラクチド-コ-グリコリド)コポリマーおよび第二生分解性ポリマーの溶解度は、全て、互いの約10MPa1/2以内であり;
(γ) 第二生分解性ポリマーの溶融温度は、ポリ(ラクチド-コ-グリコリド)コポリマーの溶融温度より低く、さらに、プロスタグランジン類似体が実質的分解を示すかまたはそのラベル強度(label strength)の約50%未満の効力を示す温度より低い;
(b) 該混合物を、第二生分解性ポリマーのより低い溶融温度に加熱する工程であって、それによって第二生分解性ポリマーがプロスタグランジン類似体およびポリ(ラクチド-コ-グリコリド)コポリマーの溶媒として機能しうる工程;および
(c) 該加熱混合物を押し出す工程であって、それによって眼内使用に適したインプラントを製造する工程。
破線結合は、シスまたはトランス配置であることができる単結合または二重結合を表し;
Aは、2〜6個の炭素原子を有するアルキエン(alkyene)またはアルケニレン基であり、該基は、1個またはそれ以上のオキシド基で中断されてもよく、1個またはそれ以上のヒドロキシ、オキソ、アルコキシまたはアルキルカルボキシル基で置換されてもよく、該アルキル基は1〜6個の炭素原子を有し;
Bは、3〜7個の炭素原子を有するシクロアルキル基であるか、またはアリール基であって、該アリール基は4〜10個の炭素原子を有するヒドロカルビルアリールおよびヘテロアリールから成る群から選択され、該ヘテロ原子は、窒素、酸素および硫黄原子から成る群から選択され;
Xは、水素、1〜6個の炭素原子を有する低級アルキル基、R5-C(=O)-またはR5-O-C(=O)-から成る群から選択され、ここでR5は1〜6個の炭素原子を有する低級アルキル基であり;
Zは、=Oであるか、または2個の水素基を表し;
R1およびR2の1つは、=O、-OHまたは-O-C(=O)-R6基であり、他方は-OHまたは-O-C(=O)-R6であるか、またはR1は=O、R2はHであり、ここでR6は1〜約20個の炭素原子を有する飽和または不飽和非環式炭化水素基であるかまたは-(CH2)mR7であり、ここでmは0〜10であり、R7は3〜7個の炭素原子を有するシクロアルキル基であるかまたは前記のように定義されるヒドロカルビルアリールまたはヘテロアリール基であり;
または、医薬的に許容されるその塩であり;
但し、Bがヘテロ原子含有側基で置換されておらず、Zが=Oである場合、Xは-OR4でないものとする。
yは、0または1であり;
xは、0または1であり;
xおよびyの両方ともが1ではなく;
Yは、アルキル、ハロ、ニトロ、アミノ、チオール、ヒドロキシ、アルキルオキシ、アルキルカルボキシおよびハロ置換アルキルから成る群から選択される基であり、該アルキル基は1〜6個の炭素原子を有し;
nは、0、または1〜3の整数であり;
R3は、=O、-OHまたは-O-C(=O)R6である]。
a) シクロペンタンヘプテノール-5-シス-2-(3α-ヒドロキシ-5-フェニル-1-トランス-ペンテニル)-3,5-ジヒドロキシ、[1α,2β,3α,5α];
b) シクロペンタンヘプテンアミド-5-シス-2-(3α-ヒドロキシ-5-フェニル-1-トランス-ペンテニル)-3,5-ジヒドロキシ、[1α,2β,3α,5α];
c) シクロペンタンN,N-ジメチルヘプテンアミド-5-シス-2-(3α-ヒドロキシ-5-フェニル-1-トランス-ペンテニル)-3,5-ジヒドロキシ、[1α,2β,3α,5α];
d) シクロペンタンヘプテニルメトキシド-5-シス-2-(3α-ヒドロキシ-5-フェニル-1-トランス-ペンテニル)-3,5-ジヒドロキシ、[1α,2β,3α,5α];
e) シクロペンタンヘプテニルエトキシド-5-シス-2-(3α-ヒドロキシ-4-メタ-クロロフェノキシ-1-トランス-ブテニル)-3,5-ジヒドロキシ、[1α,2β,3α,5α];
f) シクロペンタンヘプテニルアミド-5-シス-2-(3α-ヒドロキシ-4-メタ-クロロフェノキシ-1-トランス-ブテニル)-3,5-ジヒドロキシ、[1α,2β,3α,5α];
g) シクロペンタンヘプテニルアミド-5-シス-2-(3α-ヒドロキシ-4-メタ-トリフルオロメチル-フェノキシ-1-トランス-ブテニル)-3,5-ジヒドロキシ、[1α,2β,3α,5α];
h) シクロペンタンN-イソプロピルヘプテンアミド-5-シス-2-(3α-ヒドロキシ-5-フェニル-1-トランス-ペンテニル)-3,5-ジヒドロキシ、[1α,2β,3α,5α];
i) シクロペンタンN-エチルヘプテンアミド-5-シス-2-(3α-ヒドロキシ-5-フェニル-1-トランス-ペンテニル)-3,5-ジヒドロキシ、[1α,2β,3α,5α];
j) シクロペンタンN-メチルヘプテンアミド-5-シス-2-(3α-ヒドロキシ-5-フェニル-1-トランス-ペンテニル)-3,5-ジヒドロキシ、[1α,2β,3α,5α];
k) シクロペンタンヘプテノール-5-シス-2-(3α-ヒドロキシ-4-メタ-クロロフェノキシ-1-トランス-ブテニル)-3,5-ジヒドロキシ、[1α,2β,3α,5α];
l) シクロペンタンヘプテンアミド-5-シス-2-(3α-ヒドロキシ-4-m-クロロフェノキシ-1-トランス-ブテニル)-3,5-ジヒドロキシ、[1α,2β,3α,5α];および
m) シクロペンタンヘプテノール-5-シス-2-(3α-ヒドロキシ-5-フェニルペンチル)-3,5-ジヒドロキシ、[1α,2β,3α,5α]。
破線結合は、シスまたはトランス配置であることができる単結合または二重結合を表し;
Aは、2〜6個の炭素原子を有するアルキエンまたはアルケニレン基であり、該基は、1個またはそれ以上のオキシド基で中断されてもよく、1個またはそれ以上のヒドロキシ、オキソ、アルコキシまたはアルキルカルボキシル基で置換されてもよく、該アルキル基は1〜6個の炭素原子を有し;
Dは、2〜10個の炭素原子を有する分岐鎖または非分岐鎖アルキルまたはヘテロアルキル基、3〜7個の炭素原子を有するシクロアルキル基、またはアリール基であって、該アリール基は4〜10個の炭素原子を有するヒドロカルビルアリールおよびヘテロアリールから成る群から選択され、該ヘテロ原子は、窒素、酸素および硫黄原子から成る群から選択され;
Xは、水素、1〜6個の炭素原子を有する低級アルキル基、R5-C(=O)-またはR5-O-C(=O)-から成る群から選択され、ここでR5は1〜6個の炭素原子を有する低級アルキル基であり;
Zは、=Oであるか、または2個の水素基を表し;
R1およびR2の1つは、=O、-OHまたは-O-C(=O)-R6基であり、他方は-OHまたは-O-C(=O)-R6であるか、またはR1は=O、R2はHであり、ここでR6は1〜約20個の炭素原子を有する飽和または不飽和非環式炭化水素基であるかまたは-(CH2)mR7であり、ここでmは0〜10であり、R7は3〜7個の炭素原子を有するシクロアルキル基であるかまたは前記のように定義されるヒドロカルビルアリールまたはヘテロアリール基である]。
下記の図面は、本発明の特徴および態様を示している。
「約」は、それによって修飾されている数、範囲、値またはパラメーターが、それより10%多いおよび10%少ない数、範囲、値またはパラメーターを包含することを意味する。
本発明の方法は、環状脂質治療薬、高分子成分および有機溶媒を含んで成る第一組成物を形成する工程、第二油含有組成物を形成する工程、ならびに第一組成物および第二油含有組成物を混合する工程も含んで成ってよい。
角緑内障、高眼圧、開存性虹彩切開を伴う慢性閉塞隅角緑内障、偽剥脱性緑内障、および色素性緑内障を治療する方法において、インプラントを使用しうる。環状脂質治療薬含有インプラントを眼の結膜下腔に注射することによって、環状脂質治療薬が、房水の流れを増加させるのに有効であり、それによって眼内圧を低下させると考えられる。さらに、環状脂質治療薬を含有するインプラントの結膜下送達は、治療濃度の治療薬を眼の網膜に与えることもできる。
黄斑症/網膜変性: 黄斑変性(加齢性黄斑変性(ARMD)、例えば、非滲出性加齢性黄斑変性および滲出性加齢性黄斑変性を含む)、脈絡膜新生血管形成、網膜症(糖尿病性網膜症を含む)、急性および慢性黄斑視神経網膜症、中心性漿液性網脈絡膜症、および黄斑浮腫(類嚢胞黄斑浮腫および糖尿病性黄斑浮腫を含む)。
ブドウ膜炎/網膜炎/脈絡膜炎: 急性多発性斑状色素上皮症、ベーチェット病、バードショット脈絡網膜症、感染症(梅毒、ライム病、結核症、トキソプラスマ症)、ブドウ膜炎(中間部ブドウ膜炎(扁平部炎)および前部ブドウ膜炎を含む)、多病巣性脈絡膜炎、多発消失性白点症候群(MEWDS)、眼サルコイドーシス、後強膜炎、ほ行性脈絡膜炎、網膜下線維症、ブドウ膜炎症候群、およびフォークト-小柳-原田症候群。
血管疾患/滲出性疾患: 網膜動脈閉塞症、網膜中心静脈閉塞症、播種性血管内凝固症、網膜静脈分岐閉塞症、高血圧性眼底変化、眼虚血症候群、網膜動脈小血管瘤、コーツ病、中心窩傍(parafoveal)毛細管拡張症、半網膜静脈閉塞症、乳頭静脈炎、網膜中心動脈閉塞症、網膜動脈分岐閉塞症、頸動脈疾患(CAD)、霜状分岐血管炎、鎌状赤血球網膜症および他の異常ヘモグロビン症、網膜色素線条症、家族性滲出性硝子体網膜症、イールズ病。
外傷性/外科手術性: 交感性眼炎、ブドウ膜炎網膜疾患、網膜剥離、外傷、レーザー、PDT、光凝固、手術中の低灌流、放射線網膜症、骨髄移植網膜症。
増殖性疾患: 増殖性硝子体網膜症および網膜上膜、増殖性糖尿病性網膜症。
感染性疾患: 眼ヒストプラスマ症、眼トキソカラ症、推定眼ヒストプラスマ症候群(POHS)、眼内炎、トキソプラスマ症、HIV感染関連網膜疾患、HIV感染関連脈絡膜疾患、HIV感染関連ブドウ膜炎疾患、ウイルス性網膜炎、急性網膜壊死、進行性網膜外層壊死、真菌性網膜疾患、眼梅毒、眼結核症、びまん性片側性亜急性神経網膜炎、およびハエウジ病。
遺伝病: 色素性網膜炎、関連網膜ジストロフィーを伴う全身疾患、先天性停在夜盲症、錐体ジストロフィー、シュタルガルト病および黄色斑眼底、ベスト病、網膜色素上皮のパターンジストロフィー、X連鎖網膜分離症、ソーズビー眼底ジストロフィー、良性同心性黄斑症、ビエッティ(Biett's)結晶状ジストロフィー、弾性線維性仮性黄色腫。
網膜断裂/円孔: 網膜剥離、黄斑円孔、巨大網膜断裂。
腫瘍: 腫瘍に関連した網膜疾患、先天性RPE肥大、後部ブドウ膜メラノーマ、脈絡膜血管腫、脈絡膜骨腫、脈絡膜転移、網膜および網膜色素上皮の複合(combined)過誤腫、網膜芽細胞腫、眼底の血管増殖性腫瘍、網膜星状細胞腫、眼内リンパ性腫瘍。
その他: 点状内脈絡膜症、急性後極部多発性板状色素上皮症、近視性網膜変性、急性網膜色素上皮炎など。
ビマトプロスト微粒子の製造方法
眼内使用に好適な生分解性微粒子(ミクロスフェア)を、ビマトプロストと生分解性ポリマーとを合わすことによって製造した。即ち、ポリ乳酸(PLA)800mgをビマトプロスト200mgと合わした。その組合せを、ジクロロメタン25mLに溶解させた。次に、混合物を45℃で一晩にわたって真空において、ジクロロメタンを蒸発させた。得られた混合物はキャストシートの形態であった。キャストシートを切断し、約125μmの孔径を有する篩を粒子が通るまで、ドライアイスを用いて高剪断粉砕機で粉砕した。微粒子に存在するビマトプロストのパーセントを、高圧液体クロマトグラフィー(HPLC)を用いて分析した。微粒子からのビマトプロストの放出パーセントを、透析によって測定した。回収した粒子に残留するビマトプロストのパーセントを、HPLCによって分析した。
ビマトプロストインプラントを製造する押出法および圧縮法
ビマトプロストを、乳鉢において、生分解性ポリマー組成物と合わす。その組合せを、約96RPMに設定した振とう機で約15分間混合する。粉末ブレンドを乳鉢の側壁からかき落とし、次に、さらに15分間再混合する。混合粉末ブレンドを、特定温度で半溶融状態に合計30分間加熱し、ポリマー/薬剤メルトを形成する。
緑内障治療用のビマトプロスト/PLA/PLGA眼内インプラント
両眼に緑内障を患う72才の女性に、ビマトプロストおよびPLAとPLGAの組合せを含有する眼内インプラントを各眼に投与する。インプラントの重さは約1mgであり、約500mgのビマトプロストを含有する。1個のインプラントを、シリンジによって各眼の硝子体に配置する。約2日で、患者は眼の不快感のかなりの軽減を報告する。検査は、眼内圧が低下したことを示す:8:00AMに測定した平均眼内圧が、28mmHgから14.3mmHgに低下した。患者を約6ヵ月間監視する。眼内圧レベルは、6ヵ月間にわたって15mmHg未満に維持され、患者は減少した眼の不快感を報告する。
高眼圧治療用のビマトプロスト/PLA眼内インプラント
62才の男性が、左眼に33mmHgの眼内圧を示す。ビマトプロスト400mgおよびPLA 600mgを含有するインプラントを、トロカールによって左眼の硝子体に挿入する。患者の眼内圧を1週間にわたって毎日監視し、その後、月に1回監視する。埋め込みから1日後に、眼内圧が18mmHgに低下する。埋め込みから7日目までに、眼内圧が14mmHgで相対的に安定する。患者は、2年間にわたって高眼内圧のどのような徴候も示さない。
ビマトプロストインプラントを製造する低温溶融押出法
プロスタミド類似体ビマトプロスト((Z)-7-[1R,2R,3R,5S)-3,5-ジヒドロキシ-2-[1E,3S)-3-ヒドロキシ-5-フェニル-1-ペンテニル]シクロペンチル]-5-N-エチルヘプテンアミド)を、低温(65℃〜71℃)溶融押出法によって作製される持続放出ポリマーインプラントに組み込んだ。作製されたインプラントは、30wt%〜50wt%のビマトプロスト、および50wt%〜70wt%のポリ(D,L-ラクチド-コ-グリコリド)ポリマー(PLGA)から成っていた。
ビマトプロストインプラントを製造する超低温法
この実験において、本発明者らは、眼内投与に好適な、他のビマトプロスト含有ポリマー持続放出インプラントを作製した。約57℃もの低い温度で行うために本発明者らが開発した溶融押出法によって、インプラントを作製した。作製された例示的インプラントは、以下の物質を含有していた:15% ビマトプロスト(治療薬)、10% ポリエチレングリコール(PEG3350)(補助溶媒または第二ポリマー)、および75% ポリ(D,L-ラクチド-コ-グリコリド)ポリマー(Resomer(登録商標)RG752S、PLGA)(ポリマー担体または第一ポリマー)。
Claims (24)
- (a) 環状脂質治療薬およびポリマーを合わして混合物を形成する工程;
(b) 該混合物を約50℃〜約80℃の温度に加熱する工程;および
(c) 該加熱混合物を押し出し、それによって眼内使用に適したインプラントを製造する工程
を含んで成る、眼内インプラントの低温製造法。 - 環状脂質治療薬が、プロスタグランジン、プロスタグランジン類似体、およびそれらの混合物から成る群から選択される請求項1に記載の方法。
- 環状脂質治療薬が、ビマトプロスト、ビマトプロスト類似体、ラタノプロスト、ラタノプロスト類似体、トラボプロスト、トラボプロスト類似体、ウノプロストン、ウノプロストン類似体、プロスタグランジンE1、プロスタグランジンE1類似体、プロスタグランジンE2、プロスタグランジンE2類似体、およびそれらの混合物から成る群から選択される請求項1に記載の方法。
- 環状脂質治療薬が、ビマトプロスト、ビマトプロスト類似体、およびそれらの混合物から成る群から選択される請求項3に記載の方法。
- ポリマーが生分解性ポリマーである請求項1に記載の方法。
- 生分解性ポリマーが、ポリ乳酸、ポリグリコール酸、ポリラクチド-コ-グリコリド、およびそれらのコポリマーから成る群から選択される請求項5に記載の方法。
- ポリマーが、インプラントの約30wt%〜約95wt%を占める請求項1に記載の方法。
- 環状脂質治療薬が、インプラントの約5wt%〜約70wt%を占める請求項1に記載の方法。
- インプラントから放出される環状脂質治療薬の効力が、最大効力の少なくとも約50%である請求項1に記載の方法。
- 眼内インプラントの低温製造法であって、下記の工程を含んで成る方法:
(a) プロスタグランジン類似体および生分解性ポリマーを合わして混合物を形成する工程;
(b) 該混合物を約50℃〜約80℃の温度に加熱する工程;および
(c) 該加熱混合物を押し出し、それによって眼内使用に適したインプラントを製造する工程。 - 請求項1に記載の方法によって製造されたインプラント。
- (a)(i) 環状脂質治療薬;
(ii) 第一生分解性ポリマー;および
(ii) 第二生分解性ポリマー;
を合わして、混合物を形成する工程
(ここで、
(α) 第一生分解性ポリマーおよび第二生分解性ポリマーは、異なるポリマーであり;
(β) 環状脂質治療薬、第一生分解性ポリマー、および第二生分解性ポリマーの溶解度は、実質的に同じであり;
(γ) 第二生分解性ポリマーの溶融温度は、第一生分解性ポリマーの溶融転移温度より低い);
(b) 該混合物を、第二生分解性ポリマーのより低い溶融温度に加熱する工程であって、それによって第二生分解性ポリマーが環状脂質治療薬および第一生分解性コポリマーの溶媒として機能しうる工程(ここで、第二生分解性ポリマーの溶融温度は、環状脂質治療薬が効力の実質的損失を示す温度より低い);および
(c) 該加熱混合物を押し出す工程であって、それによって眼内使用に適したインプラントを製造する工程
を含んで成る、眼内インプラントの製造法。 - 環状脂質治療薬成分が、プロスタグランジン、プロスタグランジン類似体、およびそれらの混合物から成る群から選択される請求項12に記載の方法。
- 環状脂質治療薬が、ビマトプロスト、ビマトプロスト類似体、およびそれらの混合物から成る群から選択される請求項12に記載の方法。
- 第一生分解性ポリマーが、ポリ乳酸、ポリグリコール酸、ポリラクチド-コ-グリコリド、およびそれらのコポリマーから成る群から選択される請求項12に記載の方法。
- 第二生分解性ポリマーが、デカフルオロブタン、ポリ(イソブチレン)、ポリ(ヘキセメチレンアジパミド)、ポリプロピレン、ポリエチレンおよびポリエチレングリコールから成る群から選択される請求項12に記載の方法。
- 環状脂質治療薬、第一生分解性ポリマーおよび第二生分解性ポリマーの溶解度が、全て、互いの約10MPa1/2以内である請求項12に記載の方法。
- 環状脂質治療薬、第一生分解性ポリマーおよび第二生分解性ポリマーの溶解度が、全て、約15〜30MPa1/2以内である請求項12に記載の方法。
- 第一ポリマーが、インプラントの約30wt%〜約90wt%を占める請求項12に記載の方法。
- 第二ポリマーが、インプラントの約50wt%〜約30wt%を占める請求項12に記載の方法。
- 環状脂質治療薬が、インプラントの約5wt%〜約30wt%を占める請求項12に記載の方法。
- (a)(i) プロスタグランジン類似体であって、インプラントの約5wt%〜約30wt%を占めるプロスタグランジン類似体;
(ii) ポリ(ラクチド-コ-グリコリド)コポリマーであって、インプラントの約30wt%〜約90wt%を占めるポリ(ラクチド-コ-グリコリド)コポリマー;および
(ii) 第二生分解性ポリマーであって、インプラントの約5wt%〜約40wt%を占める第二生分解性ポリマー
を合わして、混合物を形成する工程
(ここで、
(α) ポリ(ラクチド-コ-グリコリド)コポリマーおよび第二生分解性ポリマーは、異なるポリマーであり;
(β) プロスタグランジン類似体、ポリ(ラクチド-コ-グリコリド)コポリマーおよび第二生分解性ポリマーの溶解度は、全て、互いの約10MPa1/2以内であり;
(γ) 第二生分解性ポリマーの溶融温度は、ポリ(ラクチド-コ-グリコリド)コポリマーの融点より低い);
(b) 該混合物を、第二生分解性ポリマーのより低い溶融温度に加熱する工程であって、それによって第二生分解性ポリマーがプロスタグランジン類似体およびポリ(ラクチド-コ-グリコリド)コポリマーの溶媒として機能しうる工程;および
(c) 該加熱混合物を押し出す工程であって、それによって眼内使用に適したインプラントを製造する工程(該インプラントから放出されるプロスタグランジン類似体は、少なくとも約50%の効力を有する)
眼内インプラントの製造法であって、下記の工程を含んで成る方法:。 - 眼症状の治療法であって、請求項1に記載の方法によって製造されたインプラントを眼内投与する工程を含んで成る方法。
- 眼内投与の位置が、前房、後房、硝子体腔、脈絡膜、脈絡膜上腔、網膜下腔、結膜、結膜下腔、強膜外隙、角膜内腔、角膜上腔、強膜、毛様体輪、外科的誘発無血管領域、網膜黄斑、網膜およびテノン下位置から成る群から選択される請求項23に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/612,928 US8846073B2 (en) | 2006-12-19 | 2006-12-19 | Low temperature processes for making cyclic lipid implants for intraocular use |
US11/612,928 | 2006-12-19 | ||
PCT/US2007/087139 WO2008079674A2 (en) | 2006-12-19 | 2007-12-12 | Processes for making cyclic lipid implants for intraocular use |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014029498A Division JP5826872B2 (ja) | 2006-12-19 | 2014-02-19 | 眼内使用のための環状脂質インプラントの製造法 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2010513555A true JP2010513555A (ja) | 2010-04-30 |
JP2010513555A5 JP2010513555A5 (ja) | 2011-02-03 |
JP5484911B2 JP5484911B2 (ja) | 2014-05-07 |
Family
ID=39467138
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009543071A Active JP5484911B2 (ja) | 2006-12-19 | 2007-12-12 | 眼内使用のための環状脂質インプラントの製造法 |
JP2014029498A Active JP5826872B2 (ja) | 2006-12-19 | 2014-02-19 | 眼内使用のための環状脂質インプラントの製造法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014029498A Active JP5826872B2 (ja) | 2006-12-19 | 2014-02-19 | 眼内使用のための環状脂質インプラントの製造法 |
Country Status (11)
Country | Link |
---|---|
US (5) | US8846073B2 (ja) |
EP (3) | EP3308769B1 (ja) |
JP (2) | JP5484911B2 (ja) |
AU (1) | AU2007337139B2 (ja) |
CA (1) | CA2673294C (ja) |
DK (3) | DK3308769T3 (ja) |
ES (3) | ES2588187T3 (ja) |
HK (1) | HK1253728A1 (ja) |
HU (3) | HUE053530T2 (ja) |
PL (3) | PL3308769T3 (ja) |
WO (1) | WO2008079674A2 (ja) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013525302A (ja) * | 2010-04-16 | 2013-06-20 | アラーガン、インコーポレイテッド | 眼房内ビマトプロスト注入物による眼圧低下 |
JP2016515583A (ja) * | 2013-03-27 | 2016-05-30 | フォーサイト ヴィジョンファイブ、インク.ForSight VISION5, Inc. | オキュラー・インサートおよびその使用方法 |
US10004636B2 (en) | 2009-06-03 | 2018-06-26 | Forsight Vision5, Inc. | Anterior segment drug delivery |
KR20190054221A (ko) * | 2017-11-13 | 2019-05-22 | 한동희 | 다기능성 생체적합실 |
JP2019534872A (ja) * | 2016-09-30 | 2019-12-05 | マティ セラピューティクス,インク. | 眼薬徐放性製剤およびその利用 |
US10835416B2 (en) | 2011-09-14 | 2020-11-17 | Forsight Vision5, Inc. | Ocular insert apparatus and methods |
US11224602B2 (en) | 2015-04-13 | 2022-01-18 | Forsight Vision5, Inc. | Ocular insert composition of a semi-crystalline or crystalline pharmaceutically active agent |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9498457B2 (en) | 2004-04-30 | 2016-11-22 | Allergan, Inc. | Hypotensive prostamide-containing biodegradable intraocular implants and related implants |
US7993634B2 (en) | 2004-04-30 | 2011-08-09 | Allergan, Inc. | Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods |
US20060182781A1 (en) * | 2004-04-30 | 2006-08-17 | Allergan, Inc. | Methods for treating ocular conditions with cyclic lipid contraining microparticles |
US7799336B2 (en) * | 2004-04-30 | 2010-09-21 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
US8722097B2 (en) * | 2004-04-30 | 2014-05-13 | Allergan, Inc. | Oil-in-water method for making polymeric implants containing a hypotensive lipid |
IL177762A0 (en) * | 2006-08-29 | 2006-12-31 | Arieh Gutman | Bimatoprost crystalline form i |
WO2008054725A2 (en) * | 2006-10-31 | 2008-05-08 | Surmodics Pharmaceuticals, Inc. | Spheronized polymer particles |
US8969415B2 (en) * | 2006-12-01 | 2015-03-03 | Allergan, Inc. | Intraocular drug delivery systems |
US8846073B2 (en) * | 2006-12-19 | 2014-09-30 | Allergan, Inc. | Low temperature processes for making cyclic lipid implants for intraocular use |
US10064819B2 (en) | 2008-05-12 | 2018-09-04 | University Of Utah Research Foundation | Intraocular drug delivery device and associated methods |
EP2276439A4 (en) | 2008-05-12 | 2013-11-27 | Univ Utah Res Found | INTRAOCULAR DRUG DELIVERY DEVICE AND ASSOCIATED METHODS |
US9095404B2 (en) | 2008-05-12 | 2015-08-04 | University Of Utah Research Foundation | Intraocular drug delivery device and associated methods |
US9877973B2 (en) | 2008-05-12 | 2018-01-30 | University Of Utah Research Foundation | Intraocular drug delivery device and associated methods |
US20100104654A1 (en) | 2008-10-27 | 2010-04-29 | Allergan, Inc. | Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof |
US20100247606A1 (en) * | 2009-03-25 | 2010-09-30 | Allergan, Inc. | Intraocular sustained release drug delivery systems and methods for treating ocular conditions |
RU2565445C2 (ru) * | 2010-01-22 | 2015-10-20 | Аллерган, Инк. | Внутрикамерные имплантаты с пролонгированным высвобождением терапевтического агента |
WO2011109384A2 (en) * | 2010-03-02 | 2011-09-09 | Allergan, Inc. | Biodegradable polymers for lowering intraocular pressure |
CA2804035A1 (en) * | 2010-06-30 | 2012-01-05 | Evonik Degussa Corporation | Implant processing methods for thermally labile and other bioactive agents and implants prepared from same |
US8915877B2 (en) | 2010-10-12 | 2014-12-23 | Emmett T. Cunningham, JR. | Glaucoma drainage device and uses thereof |
US9370444B2 (en) | 2010-10-12 | 2016-06-21 | Emmett T. Cunningham, JR. | Subconjunctival conformer device and uses thereof |
US8349005B2 (en) | 2011-01-03 | 2013-01-08 | Masatoshi Murata | Method for burying implant to choroid |
EP2701682A1 (en) | 2011-04-29 | 2014-03-05 | Allergan, Inc. | Solvent cast film sustained release latanoprost implant |
CA2906123C (en) | 2013-03-15 | 2021-11-30 | Allergan, Inc. | Prostamide-containing intraocular implant |
US20140271772A1 (en) * | 2013-03-15 | 2014-09-18 | Barry J. Margulies | Biodegradable subcutaneous implants and methods of making |
PL3062775T3 (pl) | 2013-10-31 | 2018-05-30 | Allergan, Inc. | Implanty wewnątrzgałkowe zawierające prostamid i sposoby ich stosowania |
US20160296627A1 (en) * | 2013-12-06 | 2016-10-13 | Envisia Therapeutics Inc. | Intracameral implant for treatment of an ocular condition |
KR20160125456A (ko) | 2014-02-26 | 2016-10-31 | 알레간 인코포레이티드 | 안구내 이식물 전달 장치 및 이의 사용 방법 |
US11458041B2 (en) | 2015-10-08 | 2022-10-04 | Ocular Therapeutix, Inc. | Punctal plug and bioadhesives |
JP7373486B2 (ja) * | 2017-07-25 | 2023-11-02 | ピーケイ・メッド | 薬物送達組成物の製造方法 |
MX2021015760A (es) | 2019-06-27 | 2022-04-06 | Layerbio Inc | Sistemas de administracion de medicamentos de dispositivos oculares. |
WO2021053171A1 (de) * | 2019-09-19 | 2021-03-25 | Amw Gmbh | Extrudierte depotform mit kontrollierter wirkstofffreisetzung |
ES2952213T3 (es) | 2020-02-06 | 2023-10-30 | Ocular Therapeutix Inc | Composiciones y métodos para tratar enfermedades oculares |
WO2023107478A1 (en) * | 2021-12-06 | 2023-06-15 | Ocular Therapeutix, Inc. | Extruded ocular inserts or implants and methods thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS632930A (ja) * | 1986-05-23 | 1988-01-07 | シンテックス(ユ−・エス・エイ)インコ−ポレイテッド | 巨大分子ポリペプチドの放出速度調節 |
US5882327A (en) * | 1997-04-17 | 1999-03-16 | Jacob; Jean T. | Long-term glaucoma drainage implant |
WO2005110424A1 (en) * | 2004-04-30 | 2005-11-24 | Allergan, Inc. | Biodegradable intraocular implants containing prostamides |
WO2006080381A1 (ja) * | 2005-01-28 | 2006-08-03 | Terumo Kabushiki Kaisha | 血管内インプラント |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4327725A (en) | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
JPS58126435U (ja) | 1982-02-19 | 1983-08-27 | オリンパス光学工業株式会社 | Ttlオ−トストロボ用絞り制御回路 |
US4521210A (en) | 1982-12-27 | 1985-06-04 | Wong Vernon G | Eye implant for relieving glaucoma, and device and method for use therewith |
US6309669B1 (en) | 1984-03-16 | 2001-10-30 | The United States Of America As Represented By The Secretary Of The Army | Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix |
US4997652A (en) | 1987-12-22 | 1991-03-05 | Visionex | Biodegradable ocular implants |
US4853224A (en) | 1987-12-22 | 1989-08-01 | Visionex | Biodegradable ocular implants |
US5164188A (en) | 1989-11-22 | 1992-11-17 | Visionex, Inc. | Biodegradable ocular implants |
KR0185215B1 (ko) | 1990-11-30 | 1999-05-01 | 요시다 쇼오지 | 서방성 안구삽입용 약제 |
MY113268A (en) | 1992-12-29 | 2002-01-31 | Insite Vision Incorporated | Plasticized bioerodible controlled delivery system |
US5443505A (en) | 1993-11-15 | 1995-08-22 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
US6369116B1 (en) | 1995-06-02 | 2002-04-09 | Oculex Pharmaceuticals, Inc. | Composition and method for treating glaucoma |
US5869079A (en) | 1995-06-02 | 1999-02-09 | Oculex Pharmaceuticals, Inc. | Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents |
EP1003569B1 (en) | 1997-08-11 | 2004-10-20 | Allergan, Inc. | Sterile bioerodible implant device containing retinoid with improved biocompatability and method of manufacture |
US6331313B1 (en) | 1999-10-22 | 2001-12-18 | Oculex Pharmaceticals, Inc. | Controlled-release biocompatible ocular drug delivery implant devices and methods |
US6743446B2 (en) | 1999-12-15 | 2004-06-01 | The Ohio State University Research Foundation | Methods for stabilizing biologically active agents encapsulated in biodegradable controlled-release polymers |
US20040175410A1 (en) | 2000-04-26 | 2004-09-09 | Control Delivery Systems, Inc. | Sustained release device and method for ocular delivery of carbonic anhydrase inhibitors |
PE20020146A1 (es) | 2000-07-13 | 2002-03-31 | Upjohn Co | Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2) |
JP2004514702A (ja) | 2000-11-29 | 2004-05-20 | オキュレックス ファーマシューティカルズ, インコーポレイテッド | 眼における移植拒絶を予防するための眼内インプラント |
WO2002089767A1 (en) | 2001-05-03 | 2002-11-14 | Massachusetts Eye And Ear Infirmary | Implantable drug delivery device and use thereof |
US7368126B2 (en) | 2002-11-06 | 2008-05-06 | Guohua Chen | Controlled release depot formulations |
US20050048099A1 (en) | 2003-01-09 | 2005-03-03 | Allergan, Inc. | Ocular implant made by a double extrusion process |
US8529927B2 (en) | 2004-04-30 | 2013-09-10 | Allergan, Inc. | Alpha-2 agonist polymeric drug delivery systems |
US20070212395A1 (en) | 2006-03-08 | 2007-09-13 | Allergan, Inc. | Ocular therapy using sirtuin-activating agents |
US8673341B2 (en) | 2004-04-30 | 2014-03-18 | Allergan, Inc. | Intraocular pressure reduction with intracameral bimatoprost implants |
WO2006031658A2 (en) | 2004-09-10 | 2006-03-23 | Allergan, Inc. | Therapeutic lacrimal canalicular inserts and related methods |
BRPI0516308A2 (pt) | 2004-10-04 | 2010-06-15 | Qlt Usa Inc | composição fluida, métodos de tratamento de uma doença ou disfunção, métodos de liberação local ou sistêmica de um agente biológico, implantes, método de formação de um implante, kit de agente biológico e usos de uma composição fluida |
US20080097335A1 (en) | 2006-08-04 | 2008-04-24 | Allergan, Inc. | Ocular implant delivery assemblies |
US8039010B2 (en) | 2006-11-03 | 2011-10-18 | Allergan, Inc. | Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier |
US8969415B2 (en) | 2006-12-01 | 2015-03-03 | Allergan, Inc. | Intraocular drug delivery systems |
US8846073B2 (en) * | 2006-12-19 | 2014-09-30 | Allergan, Inc. | Low temperature processes for making cyclic lipid implants for intraocular use |
US8231892B2 (en) | 2007-05-24 | 2012-07-31 | Allergan, Inc. | Biodegradable drug delivery system |
RU2015146211A (ru) * | 2013-04-01 | 2017-05-19 | Аллерган, Инк. | Микросферная система доставки лекарственного средства для замедленного внутриглазного высвобождения |
PL3062775T3 (pl) * | 2013-10-31 | 2018-05-30 | Allergan, Inc. | Implanty wewnątrzgałkowe zawierające prostamid i sposoby ich stosowania |
-
2006
- 2006-12-19 US US11/612,928 patent/US8846073B2/en active Active
-
2007
- 2007-12-12 HU HUE17198020A patent/HUE053530T2/hu unknown
- 2007-12-12 ES ES07855073.8T patent/ES2588187T3/es active Active
- 2007-12-12 PL PL17198020T patent/PL3308769T3/pl unknown
- 2007-12-12 ES ES13179876.1T patent/ES2657143T3/es active Active
- 2007-12-12 AU AU2007337139A patent/AU2007337139B2/en active Active
- 2007-12-12 DK DK17198020.4T patent/DK3308769T3/da active
- 2007-12-12 EP EP17198020.4A patent/EP3308769B1/en active Active
- 2007-12-12 HU HUE13179876A patent/HUE037939T2/hu unknown
- 2007-12-12 HU HUE07855073A patent/HUE030404T2/en unknown
- 2007-12-12 PL PL13179876T patent/PL2712610T3/pl unknown
- 2007-12-12 ES ES17198020T patent/ES2851748T3/es active Active
- 2007-12-12 EP EP07855073.8A patent/EP2124879B1/en active Active
- 2007-12-12 JP JP2009543071A patent/JP5484911B2/ja active Active
- 2007-12-12 PL PL07855073T patent/PL2124879T3/pl unknown
- 2007-12-12 DK DK13179876.1T patent/DK2712610T3/da active
- 2007-12-12 EP EP13179876.1A patent/EP2712610B1/en active Active
- 2007-12-12 DK DK07855073.8T patent/DK2124879T3/en active
- 2007-12-12 CA CA2673294A patent/CA2673294C/en active Active
- 2007-12-12 WO PCT/US2007/087139 patent/WO2008079674A2/en active Application Filing
-
2014
- 2014-02-19 JP JP2014029498A patent/JP5826872B2/ja active Active
- 2014-08-27 US US14/469,764 patent/US9149428B2/en active Active
-
2015
- 2015-10-06 US US14/876,436 patent/US10441543B2/en active Active
-
2018
- 2018-10-10 HK HK18112878.2A patent/HK1253728A1/zh unknown
-
2019
- 2019-10-14 US US16/600,732 patent/US20200038326A1/en not_active Abandoned
-
2021
- 2021-03-04 US US17/192,379 patent/US20210322318A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS632930A (ja) * | 1986-05-23 | 1988-01-07 | シンテックス(ユ−・エス・エイ)インコ−ポレイテッド | 巨大分子ポリペプチドの放出速度調節 |
US5882327A (en) * | 1997-04-17 | 1999-03-16 | Jacob; Jean T. | Long-term glaucoma drainage implant |
WO2005110424A1 (en) * | 2004-04-30 | 2005-11-24 | Allergan, Inc. | Biodegradable intraocular implants containing prostamides |
WO2006080381A1 (ja) * | 2005-01-28 | 2006-08-03 | Terumo Kabushiki Kaisha | 血管内インプラント |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10004636B2 (en) | 2009-06-03 | 2018-06-26 | Forsight Vision5, Inc. | Anterior segment drug delivery |
US10736774B2 (en) | 2009-06-03 | 2020-08-11 | Forsight Vision5, Inc. | Anterior segment drug delivery |
JP2013525302A (ja) * | 2010-04-16 | 2013-06-20 | アラーガン、インコーポレイテッド | 眼房内ビマトプロスト注入物による眼圧低下 |
US10835416B2 (en) | 2011-09-14 | 2020-11-17 | Forsight Vision5, Inc. | Ocular insert apparatus and methods |
JP2016515583A (ja) * | 2013-03-27 | 2016-05-30 | フォーサイト ヴィジョンファイブ、インク.ForSight VISION5, Inc. | オキュラー・インサートおよびその使用方法 |
US11224602B2 (en) | 2015-04-13 | 2022-01-18 | Forsight Vision5, Inc. | Ocular insert composition of a semi-crystalline or crystalline pharmaceutically active agent |
JP2019534872A (ja) * | 2016-09-30 | 2019-12-05 | マティ セラピューティクス,インク. | 眼薬徐放性製剤およびその利用 |
JP7088918B2 (ja) | 2016-09-30 | 2022-06-21 | マティ セラピューティクス,インク. | 眼薬徐放性製剤およびその利用 |
JP2022125050A (ja) * | 2016-09-30 | 2022-08-26 | マティ セラピューティクス,インク. | 眼薬徐放性製剤およびその利用 |
JP7324342B2 (ja) | 2016-09-30 | 2023-08-09 | マティ セラピューティクス,インク. | 眼薬徐放性製剤およびその利用 |
KR20190054221A (ko) * | 2017-11-13 | 2019-05-22 | 한동희 | 다기능성 생체적합실 |
KR102531760B1 (ko) | 2017-11-13 | 2023-05-10 | 한동희 | 다기능성 생체적합실 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5826872B2 (ja) | 眼内使用のための環状脂質インプラントの製造法 | |
US20200069847A1 (en) | Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof | |
AU2005244211B2 (en) | Sustained release intraocular implants comprising a beta adrenergic receptor antagonist and methods for treating ocular neuropathies | |
US8529927B2 (en) | Alpha-2 agonist polymeric drug delivery systems | |
JP2007535367A (ja) | エストラジオール誘導体またはエストラトポン誘導体を含有する徐放性眼内インプラント、ならびに関連する製造法 | |
KR20070004927A (ko) | 항-흥분독성 지속 방출 안내 임플란트 및 관련 방법 | |
AU2020203616B2 (en) | Processes for making cyclic lipid implants for intraocular use | |
AU2018203995B2 (en) | Processes for making cyclic lipid implants for intraocular use | |
AU2011213904B2 (en) | Sustained release intraocular implants comprising a beta adrenergic receptor antagonist and methods for treating ocular neuropathies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101208 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20101208 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20121211 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121218 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130315 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130325 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130410 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20131001 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131217 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140121 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140219 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5484911 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |